KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Optimization and validation of an ELISA assay for the determination of antibody responses to CN54gp140 and AIDSVAX BE for use in the Phase IIb PrEPVacc vaccine trial.

Ben Gombe, Claire Streatfield, Lorna Leal, Solomon Opio, Sarah Joseph, Jonathan Weber, Jonathan Hare, Pontiano Kaleebu, Jennifer Serwanga

PLoS One 17(11) e0275927

PMID36327320
PMCIDPMC9632806
DOI10.1371/journal.pone.0275927
发表日期2022-11-03
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

PrEPVacc is an international, multi-centre, double-blind vaccine study comparing experimental combination vaccine regimens including DNA/AIDSVAX BE and DNA/CN54gp140 with placebo control. Simultaneously, daily oral PrEP is compared for efficacy against daily Truvada in the context of the current PrEP availability situation at the study sites. An important clinical trial outcome is the accurate measurement of in vivo antibody titer induced through vaccination. Here we report the validation of two ELISAs for CN54gp140 and AIDSVAX BE at Uganda Virus Research Institute that demonstrates precision, specificity, and robustness for assessing the reciprocal antibody end point titer in human serum. This is a critical endpoint for determining whether vaccination can provide any protection against HIV in populations at risk of acquiring HIV.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。